Background & aims: Globally, 350 million people are at risk for HCC. Ultrasound screening is recommended but is limited by poor early-stage sensitivity and low adherence. This study evaluated whether the multi-target HCC blood test (mt-HBT) demonstrates non-inferior sensitivity for early-stage HCC compared with ultrasound and assessed its specificity.Methods: This prospective, multicenter study, conducted between… Continue reading Multi-target blood test for hepatocellular carcinoma early detection: a cross-sectional analysis of the prospective ALTUS study
Tag: HCC
Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Background/aims: The role of direct-acting antivirals (DAAs) in patients with hepatocellular carcinoma (HCC) remains uncertain due to conflicting data on virologic efficacy and long-term outcomes.Methods: This meta-analysis investigated studies reporting the sustained virologic response (SVR), recurrence, and overall survival in patients with HCC treated with DAAs.Results: Eighty-eight studies were included, comprising 8,839 patients with HCC… Continue reading Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
Background and aim: This study evaluated clinical outcomes in patients with hepatocellular carcinoma (#HCC ) treated with #durvalumab plus #tremelimumab (Dur/Tre) in routine practice, stratified by whether they fulfilled the eligibility criteria of the phase 3 HIMALAYA trial.Methods: A total of 412 patients with unresectable HCC receiving Dur/Tre at 30 Japanese institutions were enrolled. Of… Continue reading Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients
Purpose: Selective Internal Radiotherapy (SIRT) is an established treatment option for hepatocellular carcinoma (#HCC ). However, a major complication is radioembolization-induced liver disease (REILD).Methods: This retrospective study, analyzed patients treated with SIRT for HCC to identify clinical factors associated with REILD and to predict treatment response. Machine learning (#ML ) methods were applied to two… Continue reading Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients
Characteristics and outcomes of patients with #HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
Background: Atezolizumab plus bevacizumab (atezo+bev) is a standard-of-care 1L treatment for unresectable hepatocellular carcinoma (uHCC). Understanding its adoption and use, clinical outcomes, and subsequent therapies are needed.Methods: This retrospective cohort study included 550 patients with u #HCC in the US who initiated 1L atezo+bev between June 2020 and April 2023. Medical records were abstracted to… Continue reading Characteristics and outcomes of patients with #HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
Transarterial #chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic #hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
BackgroundTransarterial chemoembolisation (TACE) is standard care for unresectable, non-metastatic hepatocellular carcinoma. We aimed to evaluate the addition of lenvatinib and pembrolizumab to TACE versus dual placebo plus TACE in patients with unresectable, non-metastatic hepatocellular carcinoma.MethodsIn this multicentre, randomised, double-blind, phase 3 study (LEAP-012), patients were recruited from 137 global sites in 33 countries or regions.… Continue reading Transarterial #chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic #hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma
National guidelines on transplant selection have adopted successful downstaging to within Milan criteria (MC) as a viable option for the treatment of hepatocellular carcinoma (HCC) before liver transplant (LT). Recurrence of HCC after LT carries a poor prognosis, and treatment modalities remain challenging.Objective To establish the 10-year outcomes of patients with HCC after LT in… Continue reading Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Predicting liver cancer riskNonalcoholic fatty liver disease (NAFLD) raises the risk of developing hepatocellular carcinoma (HCC), but this risk can be difficult to quantify and disease onset can still be difficult to catch early. Fujiwara et al. developed hepatic transcriptome and serum secretome–derived signatures to predict NAFLD-related HCC in patients over 15 years of observation.… Continue reading Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced #hepatocellular carcinoma
Importance: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Despite the recent approval of several new agents, long-term disease control remains elusive for most patients. Administration of 27.12 MHz radiofrequency (RF) electromagnetic fields (EMF) by means of a spoon-shaped antenna (TheraBionic P1 device) placed on the anterior part of the tongue… Continue reading Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced #hepatocellular carcinoma
